Despite their possible redundancy, CRKL has been implicated in DiGeorge syndrome (DGS) as a dosage-sensitive gene that also shows genetic interactions with TBX1, a key 22q11.21 gene (Guris et al, 2006; Racedo et al, 2015), whereas ∼90% of DGS patients have a heterozygous 3-Mb microdeletion at 22q1.21, including these two and several other genes (McDonald-McGinn et al, 2015). Here, CRKL is linked to 22q11.2 deletion syndrome.